{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:39:15Z","timestamp":1771591155893,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cardiometabolic disorders are non-classical complications of hypercalcemic primary hyperparathyroidism (HC-PHPT), but whether this risk connotes normocalcemic PHPT (NC-PHPT) remains to be elucidated. We investigated cardiometabolic alterations in both forms of PHPT, looking for their association with indices of disease activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with HC-PHPT (<jats:italic>n<\/jats:italic>\u2009=\u200917), NC-PHPT (<jats:italic>n<\/jats:italic>\u2009=\u200917), and controls (<jats:italic>n<\/jats:italic>\u2009=\u200934) matched for age, sex, and BMI were assessed for glucose, lipid, blood pressure alterations, and history of cardiovascular events to perform a case\u2013control study at an ambulatory referral center for Bone Metabolism Diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NC-PHPT, in comparison to controls, showed similar glucose (mean\u2009\u00b1\u2009SD, 88\u2009\u00b1\u200911 vs 95\u2009\u00b1\u200922\u2009mg\/dl), total cholesterol (199\u2009\u00b1\u200925 vs 207\u2009\u00b1\u200936\u2009mg\/dl), and systolic blood pressure levels (SBP, 132\u2009\u00b1\u200923 vs 132\u2009\u00b1\u200919\u2009mmHg), together with a comparable frequency of glucose alterations (6% vs 9%), lipid disorders (41% vs 50%) and hypertension (53% vs 59%, <jats:italic>p<\/jats:italic>\u2009=\u2009NS for all comparisons). Conversely, all these abnormalities were more prevalent in HC-PHPT vs controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). When compared to NC-PHPT, HC-PHPT showed higher glucose (113\u2009\u00b1\u200931\u2009mg\/dl), total cholesterol (238\u2009\u00b1\u200943\u2009mg\/dl), and SBP levels (147\u2009\u00b1\u200915\u2009mmHg) as well as an increased frequency of glucose (41%) and lipid alterations (77%) and a higher number of cardiovascular events (18% vs 0%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 for all comparisons). Among indices of PHPT activity, calcium levels displayed a significant correlation with glucose (R\u2009=\u20090.46) and SBP values (R\u2009=\u20090.60, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>NC-PHPT is not associated with cardiovascular alterations. The predominant pathogenetic role of hypercalcemia in the development of cardiometabolic disorders could account for the absence of such alterations in NC-PHPT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-024-04063-0","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T05:01:35Z","timestamp":1728968495000},"page":"1140-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Normocalcemic primary hyperparathyroidism is not associated with cardiometabolic alterations"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-2014","authenticated-orcid":false,"given":"Marco","family":"Barale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Pusterla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Fraire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Sauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Presti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Sagone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Arvat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"4063_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","volume":"14","author":"MD Walker","year":"2018","unstructured":"M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115\u2013125 (2018). https:\/\/doi.org\/10.1038\/nrendo.2017.104","journal-title":"Nat. Rev. Endocrinol."},{"key":"4063_CR2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1002\/jbmr.4665","volume":"37","author":"S Minisola","year":"2022","unstructured":"S. Minisola, A. Arnold, Z. Belaya, M.L. Brandi, B.L. Clarke, F.M. Hannan et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J. Bone Miner. Res. 37, 2315\u20132329 (2022). https:\/\/doi.org\/10.1002\/jbmr.4665","journal-title":"J. Bone Miner. Res."},{"key":"4063_CR3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","volume":"37","author":"JP Bilezikian","year":"2022","unstructured":"J.P. Bilezikian, A.A. Khan, S.J. Silverberg, G.E.H. Fuleihan, C. Marcocci, S. Minisola et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J. Bone Miner. Res. 37, 2293\u20132314 (2022). https:\/\/doi.org\/10.1002\/jbmr.4677","journal-title":"J. Bone Miner. Res."},{"key":"4063_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.20945\/2359-3997000000556","volume":"66","author":"NE Cusano","year":"2022","unstructured":"N.E. Cusano, F. Cetani, Normocalcemic primary hyperparathyroidism. Arch. Endocrinol. Metab. 66, 666\u2013677 (2022). https:\/\/doi.org\/10.20945\/2359-3997000000556","journal-title":"Arch. Endocrinol. Metab."},{"key":"4063_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/EJE-21-1044","volume":"186","author":"J Bollerslev","year":"2022","unstructured":"J. Bollerslev, L. Rejnmark, A. Zahn, A. Heck, N.M. Appelman-Dijkstra, L. Cardoso et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur. J. Endocrinol. 186, 33 (2022). https:\/\/doi.org\/10.1530\/EJE-21-1044","journal-title":"Eur. J. Endocrinol."},{"key":"4063_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/BF03345264","volume":"26","author":"M Procopio","year":"2003","unstructured":"M. Procopio, G. Borretta, Derangement of glucose metabolism in hyperparathyroidism. J. Endocrinol. Invest. 26, 1136\u20131142 (2003). https:\/\/doi.org\/10.1007\/BF03345264","journal-title":"J. Endocrinol. Invest."},{"key":"4063_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1046\/j.1464-5491.2002.00809.x","volume":"19","author":"M Procopio","year":"2002","unstructured":"M. Procopio, G. Magro, F. Cesario, A. Piovesan, A. Pia, N. Molineri et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet. Med. 19, 958\u2013961 (2002). https:\/\/doi.org\/10.1046\/j.1464-5491.2002.00809.x","journal-title":"Diabet. Med."},{"key":"4063_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF03345719","volume":"32","author":"R Luboshitzky","year":"2009","unstructured":"R. Luboshitzky, Y. Chertok-Schaham, I. Lavi, A. Ishay, Cardiovascular risk factors in primary hyperparathyroidism. J. Endocrinol. Investig. 32, 317\u2013321 (2009). https:\/\/doi.org\/10.1007\/BF03345719","journal-title":"J. Endocrinol. Investig."},{"key":"4063_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.0300-0664.2001.01468.x","volume":"56","author":"E Hagstr\u00f6m","year":"2002","unstructured":"E. Hagstr\u00f6m, E. Lundgren, H. Lithell, L. Berglund, S. Ljunghall, P. Hellman et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin. Endocrinol. 56, 253\u2013260 (2002). https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01468.x","journal-title":"Clin. Endocrinol."},{"key":"4063_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur. J. Endocrinol. 177, 297 (2017). https:\/\/doi.org\/10.1530\/EJE-17-0485","journal-title":"Eur. J. Endocrinol."},{"key":"4063_CR11","doi-asserted-by":"publisher","unstructured":"D. Han, S. Trooskin, X. Wang, Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J. Endocrinol. Investig. (2012). https:\/\/doi.org\/10.1530\/EJE-17-0485","DOI":"10.1530\/EJE-17-0485"},{"key":"4063_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1464-5491.2009.02804.x","volume":"26","author":"F Tassone","year":"2009","unstructured":"F. Tassone, M. Procopio, L. Gianotti, G. Visconti, A. Pia, M. Terzolo et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet. Med. 26, 968\u2013973 (2009). https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02804.x","journal-title":"Diabet. Med."},{"key":"4063_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1161\/01.hyp.23.4.468","volume":"23","author":"AS Hanson","year":"1994","unstructured":"A.S. Hanson, S.L. Linas, Parathyroid hormone\/adenylate cyclase coupling in vascular smooth muscle cells. Hypertension 23, 468\u2013475 (1994). https:\/\/doi.org\/10.1161\/01.hyp.23.4.468","journal-title":"Hypertension"},{"key":"4063_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1053\/meta.2000.17708","volume":"49","author":"KC Chiu","year":"2000","unstructured":"K.C. Chiu, L.M. Chuang, N.P. Lee, J.M. Ryu, J.L. McGullam, G.P. Tsai et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 49, 1501\u20131505 (2000). https:\/\/doi.org\/10.1053\/meta.2000.17708","journal-title":"Metabolism"},{"key":"4063_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-10-0201","volume":"163","author":"P Farahnak","year":"2010","unstructured":"P. Farahnak, M. Ring, K. Caidahl, L.O. Farnebo, M.J. Eriksson, I.L. Nilsson, Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur. J. Endocrinol. 163, 461\u2013467 (2010). https:\/\/doi.org\/10.1530\/EJE-10-0201","journal-title":"Eur. J. Endocrinol."},{"key":"4063_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12020-013-0091-z","volume":"47","author":"M Procopio","year":"2014","unstructured":"M. Procopio, M. Barale, S. Bertaina, S. Sigrist, R. Mazzetti, M. Loiacono et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine 47, 581\u2013589 (2014). https:\/\/doi.org\/10.1007\/s12020-013-0091-z","journal-title":"Endocrine"},{"key":"4063_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s12020-013-0059-z","volume":"44","author":"F Tassone","year":"2013","unstructured":"F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba et al. Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine 44, 812\u2013814 (2013). https:\/\/doi.org\/10.1007\/s12020-013-0059-z","journal-title":"Endocrine"},{"key":"4063_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-012-9627-x","volume":"42","author":"I Cakir","year":"2012","unstructured":"I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419\u2013422 (2012). https:\/\/doi.org\/10.1007\/s12020-012-9627-x","journal-title":"Endocrine"},{"key":"4063_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12872-019-1093-4","volume":"19","author":"S Beysel","year":"2019","unstructured":"S. Beysel, M. Caliskan, M. Kizilgul, M. Apaydin, S. Kan, M. Ozbek et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc. Disord. 19, 106 (2019). https:\/\/doi.org\/10.1186\/s12872-019-1093-4","journal-title":"BMC Cardiovasc. Disord."},{"key":"4063_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1507\/endocrj.EJ15-0392","volume":"63","author":"F Yener Ozturk","year":"2016","unstructured":"F. Yener Ozturk, S. Erol, M.M. Canat, S. Karatas, I. Kuzu, S. Dogan Cakir et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr. J. 63, 111\u2013118 (2016). https:\/\/doi.org\/10.1507\/endocrj.EJ15-0392","journal-title":"Endocr. J."},{"key":"4063_CR21","doi-asserted-by":"publisher","unstructured":"E. Hagstr\u00f6m, E. Lundgren, J. Rastad, P. Hellman, Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur. J. Endocrinol. (2006). https:\/\/doi.org\/10.1530\/eje.1.02173","DOI":"10.1530\/eje.1.02173"},{"key":"4063_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1530\/EJE-09-1067","volume":"162","author":"KM Tordjman","year":"2010","unstructured":"K.M. Tordjman, M. Yaron, E. Izkhakov, E. Osher, G. Shenkerman, Y. Marcus-Perlman et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur. J. Endocrinol. 162, 925\u2013933 (2010). https:\/\/doi.org\/10.1530\/EJE-09-1067","journal-title":"Eur. J. Endocrinol."},{"key":"4063_CR23","unstructured":"World Health Organization & International Diabetes Federation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation. World Health Organization (2006). https:\/\/iris.who.int\/handle\/10665\/43588"},{"issue":"25","key":"4063_CR24","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","year":"2002","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Third report of the National Cholesterol Education Program (NCEP). Circulation 106(25), 3143\u20133421 (2002)","journal-title":"Circulation"},{"key":"4063_CR25","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"B. Williams, G. Mancia, W. Spiering, E. Agabiti Rosei, M. Azizi, M. Burnier et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 36, 1953\u20132041 (2018). https:\/\/doi.org\/10.1097\/HJH.0000000000001940","journal-title":"J. Hypertens."},{"key":"4063_CR26","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"F.L.J. Visseren, F. Mach, Y.M. Smulders, D. Carballo, K.C. Koskinas, M. B\u00e4ck et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227\u20133337 (2021). https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur. Heart J."},{"key":"4063_CR27","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1371\/journal.pone.0007038","volume":"4","author":"TL Kelly","year":"2009","unstructured":"T.L. Kelly, K.E. Wilson, S.B. Heymsfield, Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One 4, 7038 (2009). https:\/\/doi.org\/10.1371\/journal.pone.0007038","journal-title":"PLoS One"},{"key":"4063_CR28","doi-asserted-by":"publisher","unstructured":"M.A. Stults-Kolehmainen, F. Mach, P.R. Stanforth, J.B. Bartholomew, T. Lu, C.J. Abolt, R. Sinha, DXA estimates of fat in abdominal, trunk and hip regions varies by ethnicity in men. Nutr. Diabetes (2013). https:\/\/doi.org\/10.1038\/nutd.2013.","DOI":"10.1038\/nutd.2013"},{"key":"4063_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/BF03346443","volume":"31","author":"MD Walker","year":"2008","unstructured":"M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925\u2013931 (2008). https:\/\/doi.org\/10.1007\/BF03346443","journal-title":"J. Endocrinol. Invest."},{"key":"4063_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/sj.jhh.1001907","volume":"19","author":"C Letizia","year":"2005","unstructured":"C. Letizia, P. Ferrari, D. Cotesta, C. Caliumi, R. Cianci, S. Cerci et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J. Hum. Hypertens. 19, 901\u2013906 (2005). https:\/\/doi.org\/10.1038\/sj.jhh.1001907","journal-title":"J. Hum. Hypertens."},{"key":"4063_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0002-9343(97)00270-2","volume":"104","author":"RA Wermers","year":"1998","unstructured":"R.A. Wermers, S. Khosla, E.J. Atkinson, C.S. Grant, S.F. Hodgson, W.M. O'fallon et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am. J. Med. 104, 115\u2013122 (1998). https:\/\/doi.org\/10.1016\/s0002-9343(97)00270-2","journal-title":"Am. J. Med."},{"key":"4063_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1152\/ajprenal.1990.259.2.F210","volume":"259","author":"AF Perna","year":"1990","unstructured":"A.F. Perna, G.Z. Fadda, X.J. Zhou, S.G. Massry, Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am. J. Physiol. 259, 210\u2013216 (1990). https:\/\/doi.org\/10.1152\/ajprenal.1990.259.2.F210","journal-title":"Am. J. Physiol."},{"key":"4063_CR33","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/ndt\/12.5.933","volume":"12","author":"D Fliser","year":"1997","unstructured":"D. Fliser, E. Franek, P. Fode, A. Stefanski, C. Schmitt, M. Lyons et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol. Dial. Transplant. 12, 933\u2013938 (1997). https:\/\/doi.org\/10.1093\/ndt\/12.5.933","journal-title":"Nephrol. Dial. Transplant."},{"key":"4063_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.surg.2009.09.041","volume":"146","author":"L Brunaud","year":"2009","unstructured":"L. Brunaud, A. Germain, R. Zarnegar, M. Rancier, S. Alrasheedi, C. Caillard et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146, 1035\u20131041 (2009). https:\/\/doi.org\/10.1016\/j.surg.2009.09.041","journal-title":"Surgery"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04063-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:09:57Z","timestamp":1731323397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04063-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04063-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee (Comitato Etico Interaziendale A.O.U. Citt\u00e0 della Salute e della Scienza di Torino\u2014A.O. Ordine Mauriziano\u2014A.S.L. Citt\u00e0 di Torino) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}